Drug Monograph

Drug/Drug Class:	**Ritalin LA™ (methylphenidate hydrochloride) extended-release capsule / ADHD**
Prepared for:	MO HealthNet
Prepared by:	Xerox Heritage, LLC

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Ritalin LA™ is now available in an extended-release capsule containing 60 mg of methylphenidate hydrochloride.
Manufacturer:	Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936
Indications:	Ritalin LA™ is indicated for the treatment of Attention Deficit Hyperactivity Disorder.
Costs:	$9.11 per capsule of Ritalin LA™ 60 mg. Wholesale Acquisition Cost
Summary of Findings:	The Division recommends adding this drug to the current ADHD clinical edit.
Status Recommendation:	☐ Prior Authorization (PA) Required ☐ Open Access ☐ Fiscal Edit ☒ Clinical Edit
Type of PA Criteria:	☐ Increased Risk of ADE ☐ Non-Preferred Agent ☒ Appropriate Indications ☐ No PA Required

Prepared By: Luke Boehmer, Pharm. D.
Date: November 9, 2015

© 2015 Xerox Heritage, LLC All Rights Reserved.